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BACKGROUND: Fibrinogen concentrate is the
preferred choice for fibrinogen replacement in congenital
fibrinogen deficiency. This study investigated hemostatic
efficacy of a new plasma-derived, double virus-
inactivated (using two dedicated virus inactivation/
elimination steps) human fibrinogen concentrate for on-
demand treatment of bleeding episodes (BEs) and
surgical prophylaxis.
STUDY DESIGN AND METHODS: In this planned
interim analysis of a prospective, multinational Phase III
study (NCT02267226), 13 patients with afibrinogenemia
(12 years) received fibrinogen concentrate (FIBRYGA,
Octapharma AG). Hemostatic efficacy was assessed by
investigators and an independent data monitoring and
endpoint adjudication committee (IDMEAC) using
objective four-point criteria and by thromboelastometry
maximum clot firmness (MCF).
RESULTS: Fibrinogen concentrate was used on-
demand to treat 23 BEs in 11 patients, with 21 (91.3%)
requiring a single infusion only. Treatment success was
95.7% (90% confidence interval [CI], 0.81-1.00;
assessment missing for one BE) by investigators and
100% (90% CI, 0.88-1.00) by IDMEAC. Mean MCF
increased significantly from 0.0 to 6.5 mm (95% CI, 5.65-
7.40; p<0.0001) at 1 hour postinfusion of a median
(range) dose of 58.8 (33.9-101.7) mg/kg per BE. Four
patients received fibrinogen concentrate as surgical
prophylaxis, with intraoperative and postoperative
treatment success rated 100% (90% CI, 0.50-1.00) by
investigators and IDMEAC (median [range] dose per
surgery 93.5 [34.1-225.4] mg/kg). No additional
hemostatic interventions were required. No deaths,
thromboses, or seroconversions were reported.
CONCLUSION: These data showed that the new
fibrinogen concentrate was efficacious for on-demand
treatment of acute bleeding and surgical prophylaxis in
congenital afibrinogenemia patients.
ABBREVIATIONS: AE(s)5 adverse event(s); BE(s)5bleeding
episode(s); FAS5 full analysis set; IDMEAC5 independent data
monitoring and endpoint adjudication committee; IVR5 in vivo
recovery; MCF5maximum clot firmness.
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F
ibrinogen is the most abundant clotting factor in
the human circulation. It plays a pivotal role in
hemostasis by promoting clot formation, stabili-
zation, and platelet (PLT) aggregation.1 Fibrino-
gen is converted to insoluble fibrin monomers in a
polymerization reaction catalyzed by the serine protease
thrombin. The resultant fibrin monomers form a stable,
cross-linked lattice with PLTs that impedes, and ultimately
stops, blood loss.
Physiologic levels of fibrinogen are typically in the
range 150 to 450 mg/dL.2 In a number of inherited disor-
ders, however, quantitative defects in circulating fibrino-
gen mean that levels are reduced (hypofibrinogenemia; 50
to <150 mg/dL)3 or completely absent (afibrinogenemia).
The quality of circulating fibrinogen may also be affected
(dysfibrinogenemia). Afibrinogenemia, the rarest fibrino-
gen deficiency, has an estimated prevalence of one in 1
million4,5 and is often diagnosed in the newborn period. It
is associated with a variable bleeding tendency that may
be life-threatening and is the result of spontaneous or
trauma-related bleeds,3 most frequently affecting the
umbilical cord, skin, gastrointestinal and genitourinary
tracts, and muscles/joints.4,6-8 Bleeding in patients with
hypofibrinogenemia follows a similar clinical presentation
but is generally milder and may be asymptomatic prior to
a bleeding episode (BE), typically the result of trauma or
surgery.3,4
Treatment of patients with congenital fibrinogen defi-
ciency centers on supplementation of endogenous fibrin-
ogen levels. Although infusion with fresh-frozen plasma
(FFP) or cryoprecipitate remain options for fibrinogen
replacement and are used in some countries,9,10 their use
is limited by variable fibrinogen content, large infusion
volumes, or risk of pathogen transmission.11,12 Instead,
fibrinogen supplementation with human fibrinogen con-
centrate is now considered the treatment of choice for
patients with congenital fibrinogen deficiency.13-15 Com-
pared with cryoprecipitate (and FFP), human fibrinogen
concentrate is of greater purity, does not require blood
group matching, can be prepared and administered more
quickly, and enables more accurate and standardized
dosing.11,16
For patients with congenital fibrinogen deficiency,
the primary therapeutic goal of fibrinogen supplementa-
tion is to achieve plasma fibrinogen levels of approxi-
mately 100 mg/dL for a minor BE or minor surgery and
150 mg/dL for a major BE or major surgery, as described
by Peyvandi and colleagues.17 To this end, fibrinogen con-
centrate is used as supplementation for on-demand treat-
ment of acute BEs and for surgical prophylaxis.18,19
A new plasma-derived human fibrinogen concentrate
has been developed that, unlike alternative concentrates
currently licensed for use, is prepared using two dedicated
virus inactivation/elimination steps (solvent/detergent
and nanofiltration). In a recent Phase II study addressing
pharmacokinetics, surrogate efficacy, and safety of this
new human fibrinogen concentrate, we reported larger
area under the concentration–time curve and slower
clearance for the new fibrinogen concentrate relative to
active control (a different fibrinogen concentrate) in
patients with afibrinogenemia.20 Both fibrinogen concen-
trates were comparable in other pharmacokinetic param-
eters, ability to restore clot strength (maximum clot
firmness [MCF]), and safety and tolerability.20
Here, we now report the results of a planned interim
analysis of the follow-up, ongoing, multinational, open-
label Phase III efficacy and safety study in patients with
congenital fibrinogen deficiency. For the first time in this
rare disease setting, we use objective efficacy criteria as a
robust method to determine the hemostatic efficacy of
the new fibrinogen concentrate for on-demand treatment
of acute BEs and for prophylaxis before surgery.
MATERIALS AND METHODS
Study design
FORMA-02 (NCT02267226) is an ongoing multinational,
multicenter, prospective, open-label, uncontrolled, Phase
III efficacy and safety study in patients with congenital
fibrinogen deficiency. The study began in October 2014
and is being conducted across 13 centers in nine countries
(Bulgaria, India, Iran, Lebanon, Russia, Saudi Arabia, Tur-
key, United Kingdom, United States) with a target enroll-
ment of 24 patients. This planned interim analysis
included 13 patients with afibrinogenemia.
All patients received fibrinogen concentrate
(FIBRYGA, Octapharma AG) to treat an acute BE or as sur-
gical prophylaxis. Recommended intravenous (IV) injec-
tion of fibrinogen concentrate was individually dosed to
achieve a target plasma fibrinogen level of 100 mg/dL
(accepted lower limit, 80 mg/dL) for minor bleeding or
minor surgery and 150 mg/dL (accepted lower limit,
130 mg/dL) for major bleeding or major surgery. Patients
therefore received one or more infusions of fibrinogen
concentrate for each BE or surgery. After the first and each
subsequent infusion, patients were monitored over a
treatment observation period. During this period, the rec-
ommendation for additional infusions was determined by
measuring plasma fibrinogen levels daily and also within
1 hour after each additional infusion. The treatment
observation period for each patient was defined according
to the severity of the event, lasting at least 3 days for
minor bleeding or minor surgery and at least 7 days for
major bleeding or major surgery. The actual treatment
duration was determined by the investigator based on
their judgment of the patient’s condition. All bleeding pat-
ents were followed for a 30-day safety observation period.
LISSITCHKOV ET AL.
414 TRANSFUSION Volume 58, February 2018
Fibrinogen concentrate was given as an IV bolus
injection at a maximum speed of 5 mL/min. Study medi-
cation was packed and labeled according to local regula-
tions in vials containing 1 g of lyophilized fibrinogen
concentrate powder, reconstituted with 50 mL of water for
injection. A single batch of fibrinogen concentrate was
used throughout the study.
The study was conducted in accordance with Good
Clinical Practice (CPMP/ICH/135/95), the Declaration of
Helsinki and national law, and under a US Investigational
New Drug (IND) application (IND number 014777). In
accordance with local requirements, the study protocol
received written approval from the country regulatory
authorities, independent ethics committees, and institu-
tional review boards. All patients gave written informed
consent.
Study population and inclusion and exclusion
criteria
Patients at least 12 years old with a documented diagnosis
of congenital fibrinogen deficiency—manifesting as afibri-
nogenemia or severe hypofibrinogenemia—or with
plasma fibrinogen activity of less than 50 mg/dL (or levels
below the detection limit of the local assay) were included
in the study if they were expected to require on-demand
treatment for an acute BE (spontaneous or after trauma)
or for surgical prophylaxis before planned elective surgery.
Primary exclusion criteria were a life expectancy of less
than 6 months, diagnosis with a bleeding disorder other
than congenital fibrinogen deficiency (including dysfibri-
nogenemia), prophylactic treatment with a fibrinogen
concentrate, or treatment with any fibrinogen concentrate
or other fibrinogen-containing blood product within 2
weeks before the start of treatment for the BE or surgery.
Patients were also excluded if they had been treated with
any coagulation-active drug within 1 week before treat-
ment for the BE or surgery or had a history of hypersensi-
tivity to the study medication or human plasma proteins.
Objectives
The objectives of the study were to demonstrate the effi-
cacy of fibrinogen concentrate for on-demand treatment
of acute BEs and prevention of intra- and postoperative
bleeding. We also aimed to evaluate the association
between clinical assessment of hemostatic efficacy and
the surrogate efficacy endpoint of plasma MCF and to
investigate the peak target plasma fibrinogen levels during
treatment and the safety of fibrinogen concentrate.
Hemostatic efficacy
Clinical assessment
Hemostatic efficacy of fibrinogen concentrate for on-
demand treatment and surgical prophylaxis was con-
ducted using separate objective four-point rating criteria.
These criteria are based on key events related to bleeding,
including cessation of bleeding, use of other hemostatic
interventions, and hemoglobin (Hb) level. The use and
success of such criteria have been reported for the clinical
investigation of other congenital bleeding disorders.21,22
All clinical efficacy assessments were also adjudicated by
an independent data monitoring and endpoint adjudica-
tion committee (IDMEAC). Below we provide a detailed
summary of each of the criteria sets (the complete, verba-
tim rating criteria as used in the clinic setting are provided
in Table S1, available as supporting information in the
online version of this paper).
For on-demand treatment of BE, hemostatic efficacy
was assessed by the treating physician: excellent (immedi-
ate and complete cessation of bleeding in the absence of
other hemostatic intervention or <10% decrease in Hb
compared to before infusion), good (eventual complete
cessation of bleeding or <20% decrease in Hb), moderate
(incomplete cessation of bleeding and additional
hemostatic intervention required or 20%-25% decrease in
Hb), and none (no cessation of bleeding and alternative
hemostatic intervention required or >25% decrease in Hb).
For surgical prophylaxis, intraoperative efficacy was
assessed by the surgeon at the end of surgery, evaluating
intraoperative blood loss (excluding due to unexpected
complications) relative to the same type of procedure per-
formed in an age- and sex-matched patient with normal
hemostasis: excellent (blood loss was lower than or equal
to the average expected), good (blood loss was higher
than average expected but lower or equal to the maximal
expected), moderate (blood loss was higher than maximal
expected but hemostasis was controlled), and none
(hemostasis was uncontrolled requiring a change in clot-
ting factor replacement regimen).
Postoperative efficacy was assessed by the hematolo-
gist, evaluating postoperative blood loss not due to com-
plications of surgery and the use of fibrinogen
concentrate: excellent (no bleeding or oozing and all
bleeding was controlled with fibrinogen concentrate as
anticipated), good (no bleeding or oozing, and control of
bleeding required increased dosing with fibrinogen con-
centrate or additional infusions not originally anticipated),
moderate (some bleeding and oozing and control of
bleeding required increased dosing with fibrinogen con-
centrate or additional infusions not originally anticipated),
and none (extensive uncontrolled bleeding and oozing
and control of bleeding required use of an alternate fibrin-
ogen concentrate).
Clot strength: MCF
As a surrogate measure of hemostatic efficacy, MCF in
plasma was quantified using thromboelastometry
(ROTEM, Tem International GmbH). In each case, MCF
was determined before (30 min) the first infusion and at
1 hour after the end of the first and last infusions. Changes
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in MCF relative to before infusion were also calculated.
Assays were performed using frozen citrated plasma sam-
ples and the exTEM activator and were performed by a
central laboratory responsible for clot strength measure-
ments as well as fibrinogen measurements in plasma and
inhibitor testing (Lund University, Malm€o University Hos-
pital). As previously described, the fibrinogen content
(and resultant fibrin network) primarily define the MCF
when measured in plasma samples.19
Assessment of recovery and fibrinogen levels
For the first and last infusions to treat each BE, incremen-
tal in vivo recovery (IVR) was calculated as the maximum
increase in plasma fibrinogen activity at 1 and 3 hours
after infusion compared with preinfusion levels. For all
other infusions to treat BEs, IVR was assessed at 1 hour
postinfusion. For surgical prophylaxis, IVR was calculated
for the loading dose of the first surgical infusion. Plasma
fibrinogen levels (mg/dL) were measured by the Clauss
method in the central laboratory (Malm€o University Hos-
pital) before the first fibrinogen concentrate infusion for
each BE. Thereafter, levels were measured daily, including
before and within 1 hour after each additional fibrinogen
concentrate infusion if required.
Safety
Safety was assessed by monitoring vital signs (systolic and
diastolic blood pressure, pulse rate, respiratory rate, body
temperature), physical examinations, and routine clinical
laboratory assessments (including coagulation variables)
at predefined points throughout the study. Adverse events
(AEs), including thromboembolic complications and signs
of allergic or hypersensitivity reactions, were recorded.
Immunogenicity was evaluated before infusion and on
Days 14 and 30 postinfusion, and thrombogenicity was
assessed by measuring plasma levels of prothrombin frag-
ments 1 (F1) and 2 (F2) and D-dimer at a central labora-
tory (Synlab Pharma Institute).
Statistical analysis
This planned interim analysis was performed after 11
patients had been treated for at least one acute BE (data
cutoff March 2016). The primary focus of the analysis is
the full analysis set (FAS)-bleeding population, defined
according to the intention-to-treat principle and compris-
ing 11 patients who received at least one infusion of study
medication and presented with an acute BE (n5 23 BEs in
total). The surgical prophylaxis population comprises four
patients (four surgeries; two patients had both surgery
and BE), and the total safety population is 13 patients.
This planned interim analysis was descriptive and
focused on overall clinical assessment of hemostatic effi-
cacy for all BEs. Based on the hemostatic efficacy four-
point rating scales described, “treatment success” for a BE
or surgical prophylaxis was defined as a rating of excellent
or good (vs. moderate and none). Success rate was the
proportion of patients with treatment success. The null
hypothesis was that the proportion of patients with treat-
ment success (denoted p) was lower than or equal to 0.7
(Ho: p 0.7), versus the alternative hypothesis that the pro-
portion was greater than 0.7 (HA: p > 0.7). This was tested
by comparing the lower limit of the two-sided confidence
interval (CI) for p versus the predefined threshold of 0.7.
RESULTS
Patient characteristics
At the time of this planned interim analysis, 23 patients
had been screened for the study, of which 13 had been
treated with fibrinogen concentrate and were included in
the analysis reported here (Fig. 1). All patients had afibri-
nogenemia (plasma fibrinogen activity< 30 mg/dL at
screening) and were older than 12 years of age. The
median (range) age of the patients was 30.0 (13-53) years.
Two patients were between 12 and 18 years. Of the 13
patients, seven (53.8%) were male and nine (69.2%) were
of white race (Table 1). Data presented are for the FAS-
bleeding population (n5 11), unless otherwise indicated.
Hemostatic efficacy for on-demand treatment of all
BEs
We assessed the hemostatic efficacy of fibrinogen concen-
trate treatment in 11 patients who experienced 23 BEs (16
spontaneous, seven due to trauma), all of which were
minor. For 21 of the 23 (91.3%) BEs, a single infusion of
fibrinogen concentrate was required to treat the BE; the
remaining two BEs were each treated with two infusions
depending on the local fibrinogen levels and the discre-
tion of the investigator. The median (range) dose of fibrin-
ogen concentrate administered per BE and per infusion
Patients screened*
(N=23)
Patients treated†
(N=13)
SAFETY
population
(N=13)
FAS-Bleeding
population
(N=11)
FAS-Surgery
population
(N=4)
23 bleeding 
episodes
4 surgeries 
(3 minor, 1 major)
Fig. 1. Patient disposition. *“Patients screened” were
screened and gave consent. †“Patients treated” received
fibrinogen concentrate for the treatment of BEs or surgical
prophylaxis and were included in this interim analysis. Two
patients had both surgery and BE.
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was 58.8 (33.9-101.7) and 57.5 (33.9-71.4) mg/kg, respec-
tively (Table 2).
Treatment success for the 23 BEs was 95.7% (90% CI,
0.81-1.00) based on investigator rating using the four-
point scale (19 excellent, three good; for one BE, the rating
was missing due to the patient suffering an accident
[a fall] shortly after the BE treatment and consequently
requiring surgery for a patella injury; due to the missing
BE rating this assessment was assigned as a “failure”;
Table 3). The success of treatment for the two pediatric
(18 years) patients was rated excellent by the investi-
gators. The lower limit of the success rate was higher than
the 0.7 threshold, fulfilling the preestablished statistical
criterion for confirming the efficacy of fibrinogen concen-
trate. Treatment success according to IDMEAC review was
100% (90% CI, 0.88-1.00), with treatment of all 23 BEs, in
adults (n5 21) and pediatric (n5 2) patients alike, rated
as excellent. The independent IDMEAC ratings were
mostly in line with the investigators’ ratings and, as per
protocol, were considered the final assessment. No addi-
tional hemostatic interventions, such as blood transfu-
sions or other blood products, were required in any
patients. The hemostatic efficacy of fibrinogen concen-
trate for treating the 23 BEs was also demonstrated by a
significant increase in mean MCF from 0.0 mm at baseline
to 6.5 mm (95% CI, 5.65-7.40; p< 0.0001) at 1 hour after
the first fibrinogen concentrate infusion (Fig. 2).
Hemostatic efficacy for surgical prophylaxis of
bleeding
We assessed the efficacy of fibrinogen concentrate as pro-
phylaxis before surgery in four patients (two of these
patients also had a BE in the study). Each of these four
patients underwent a single surgical procedure: three
were minor (left knee radioisotope synovectomy, dental
extraction of one tooth, circumcision), and one was major
(right eye enucleation with socket reconstruction). A load-
ing dose (median [range], 70.0 [65.8-102.6] mg/kg) before
surgery was administered in three cases; in the remaining
case, fibrinogen concentrate had been administered
shortly before surgery to treat a separate BE and the inves-
tigator therefore deemed it unnecessary to administer a
loading dose. The median (range) total dose per surgery
was 93.5 (34.1-225.4) mg/kg with a median dose per infu-
sion of 26.0 mg/kg, including preoperative loading dose
and infusions given after the end of surgery as needed
depending on the local fibrinogen levels and the discre-
tion of the investigator. No maintenance doses during
TABLE 1. Demographic and clinical characteristics*
Variable
Mean (6SD)
or number (%) Median (range)
Age at informed
consent (years)
30.7 (613.0) 30.0 (13.0-53.0)
Height (cm) 164.8 (612.2) 167.0 (149.0-190.0)
Weight (kg) 70.9 (616.8) 72.0 (34.0-99.0)
BMI (kg/m2) 26.0 (65.6) 25.8 (14.3-39.6)
Sex
Male
Female
7 (53.8)
6 (46.2)
Race
Caucasian
Asian
10 (76.9)
3 (23.1)
Congenital fibrinogen
deficiency
Afibrinogenemia 13 (100)
Hypofibrinogenemia 0 (0)
*Safety population, n513.
BMI5 body mass index.
TABLE 2. Fibrinogen concentrate dosages for the treatment of all BEs and administered for surgeries*
Variable Mean (6SD) Median (range)
All BEs (FAS-bleeding population)
Number of exposure-days/infusions 1.1 (60.29) 1 (1-2)
Fibrinogen concentrate dose per BE
mg 4652 (61027) 5,000 (2,000-6,000)
mg/kg 61.2 (611.5) 58.8 (33.9-101.7)
Fibrinogen concentrate dose per infusion
mg 4280 (61100) 5,000 (2,000-6,000)
mg/kg 56.3 (611.0) 57.5 (33.9-71.4)
Surgeries (FAS-surgery population)†
Total dose per surgery
mg 8435 (66417) 6,620 (3,000-17,500)
mg/kg‡ 111.6 (683.9) 93.5 (34.1-225.4)
Preoperative loading dose (mg/kg)§ 79.5 (620.1) 70.0 (65.8-102.6)
Infusions after end of surgery (mg/kg)§ 20.8 (67.9) 20.5 (12.8-34.1)
Total dose per infusion/exposure-day
mg 2595 (62112) 2,000 (1,000-8,000)
mg/kg 34.3 (627.8) 26.0 (12.8-102.6)
* For BEs, n523 BEs in 11 patients; for surgeries, n5 4 surgeries in four patients.
† Unless otherwise stated, data are based on a total of n513 infusions.
‡ No maintenance doses during surgery were required in any patient.
§ n5 3 infusions for preoperative loading dose, and n510 for infusions after the end of surgery.
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surgery were required in any patient. One minor surgery
required one postoperative infusion, another minor sur-
gery required two postoperative infusions, and the major
surgery required seven postoperative infusions. Further
details of fibrinogen concentrate dosages administered for
surgeries are provided in Table 2.
The intraoperative and postoperative efficacy of
fibrinogen concentrate was demonstrated with treatment
success rates of 100% (90% CI, 0.5-1.0) in each case, as
determined by the surgeon or hematologist and indepen-
dently by the IDMEAC using the four-point hemostatic
efficacy rating scales (Fig. 3). For all three minor surgeries,
TABLE 3. Hemostatic efficacy of a new fibrinogen concentrate for treatment of BEs (FAS-bleeding population)*
Investigator IDMEAC
Efficacy rating Number (%) 90% CI§ Number (%) 90% CI§
Four-point efficacy scale
Excellent 19 (82.6) 23 (100)†
Good 3 (13.0)† 0
Moderate 0 0
None 0 0
Missing 1 (4.4)
Two-point efficacy scale‡
Success 22 (95.7)k 0.81, 1.00 23 (100) 0.88, 1.00
Failure 1 (4.3%)k 0
* n5 23 BEs in 11 patients.
† For one patient experiencing one BE, hemostatic efficacy was rated good by the investigator and excellent by the IDMEAC despite under-
dosing with new fibrinogen concentrate, with resulting maximum plasma fibrinogen levels of not more than 90% of the 100 mg/dL target.
Analyses that added this BE to the per-protocol data set showed no impact on overall hemostatic efficacy (21/22 [95.5%] BEs rated as
treatment success by investigator and 22/22 [100%] BEs rated as treatment success by IDMEAC).
‡ Efficacy rating of excellent or good indicated success and efficacy rating of moderate or none indicated failure.
§ 90% CI for the success rate was calculated according to Blyth-Still-Casella interval for the proportion of patients with successful hemostatic
efficacy using a predefined threshold of 0.7.
k For the purpose of success rate calculation, the missing assessment was considered a failure.
Fig. 2. Maximum clot firmness at baseline and 1 hour after
the first fibrinogen concentrate infusion for all BEs (FAS-
bleeding population). n523 BEs in 11 patients. Boxplots
show the median (horizontal line), mean (diamond), upper
and lower quartiles (box ends), and minimum and maximum
values at 1.53 interquartile range (whiskers).
Fig. 3. Intraoperative (A) and postoperative (B) hemostatic
efficacy of fibrinogen concentrate in surgical prophylaxis
(FAS-surgery population). n54 surgeries in four patients.
Efficacy rating of excellent or good indicated success, and
efficacy rating of moderate or none indicated failure. Rat-
ings of good were all related to the one major surgery per-
formed (right eye enucleation with socket reconstruction).
(A), surgeon; w, IDMEAC. (B) , hematologist; w, IDMEAC.
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intra- and postoperative efficacy was rated as excellent,
and for the one major surgery was rated as good. No cases
required additional hemostatic interventions.
Response to fibrinogen concentrate
Assessment of incremental IVR was conducted for the first
infusion of fibrinogen concentrate used for the treatment
of BEs. The mean6 SD IVR for the 23 BEs in 11 patients
was 1.846 0.41 mg/dL/(mg/kg). A slightly lower IVR of
1.426 0.38 mg/dL/(mg/kg) was observed for the loading
dose prior to surgery (FAS-surgery population; n5 3 sur-
geries in three patients as one patient received fibrinogen
concentrate for bleeding immediately before surgery and
no IVR could therefore be calculated).
Mean plasma fibrinogen levels after the 23 BEs in the
11 patients increased from preinfusion levels after fibrino-
gen concentrate administration (Fig. 4). The largest mean
increase was observed at 1 hour (104.56 18.3 mg/dL,
mean6SD), with a similar level observed at 3 hours
(95.96 18.9 mg/dL, mean6SD). The minimum observa-
tion period prescribed in the protocol was 3 days for a
minor BE, so there were fewer recorded data points avail-
able beyond this time point. Only two patients had maxi-
mum plasma fibrinogen levels of not more than 90% of
the 100 mg/dL target for minor BEs (43 mg/dL [due to
underdosing] and 87 mg/dL). For surgical prophylaxis, the
three patients who underwent minor surgery achieved
plasma fibrinogen levels approaching or exceeding the tar-
get level of 100 mg/dL and above the accepted lower limit
of 80 mg/dL, with levels measured at the end of surgery of
89, 98, and 139 mg/dL. The single patient who underwent
major surgery had a plasma fibrinogen level of 220 mg/dL
at the end of surgery, indicating that the 150 mg/dL target
was achieved. Additional doses were recommended if the
fibrinogen levels fell below the targets described in the
protocol and were based on the clinical judgment of the
treating physician and the status of the patient.
Safety
Safety data were available for all 13 patients treated with
fibrinogen concentrate, either as on-demand therapy for
an acute BE or for surgical prophylaxis. No deaths or
thrombotic events were reported and no patients devel-
oped fibrinogen antibodies during the study (two patients
with a history of on-demand treatment with cryoprecipi-
tate were positive for fibrinogen antibodies before the first
infusion of fibrinogen concentrate but this was not seen
to impact on the observed efficacy and IVR of fibrinogen
concentrate treatment).
In total, 16 AEs in seven patients (53.8%) were
reported (Table 4). Of these, the majority (13/16, 81.3%)
were mild and included AEs such as asthenia and vomit-
ing. Only a single AE (mild skin reaction) was deemed pos-
sibly related to fibrinogen concentrate administration and
this resolved upon treatment with diphenhydramine and
steroids. One moderate and two severe AEs were reported,
none of which were related to treatment. The moderate
AE was an arthropod sting. The two severe SAEs (patella
fracture and ligament rupture in the left knee), which
occurred in one patient, were due to a fall. These two
severe AEs were the only serious AEs to occur in the study.
Fig. 4. Fibrinogen plasma levels after the first fibrinogen con-
centrate infusion for all BEs (FAS-bleeding population).
n523 BEs in 11 patients. Time points on the x-axis repre-
sent days on which fibrinogen activity was tested (by the
central laboratory). Circles indicate mean values and hori-
zontal bars the upper and lower SE values. n5number of
observations; post-inf5postinfusion; pre-inf5preinfusion;
SE5 standard error of the mean.
TABLE 4. Summary of AEs (safety population)*
Number of AEs†
AE 16
Patients with AE, n (%) 7 (53.8)
Severity of AE
Mild
Moderate
Severe
13
1
2‡
Relatedness to treatment (probably
or possibly related)
1§
AE leading to discontinuation 0
Death 0
* n5 38 infusions in 13 patients. Unless otherwise indicated,
numbers are the number of AEs.
† AEs include TEAEs, occurring between the start of the first
fibrinogen concentrate infusion and the end of each 30-day
observation and follow-up period, and non-TEAEs, AEs occur-
ring outside of the follow-up period.
‡ Patella fracture and ligament rupture of the left knee in one
patient due to a fall.
§ Mild skin reaction (itchiness and redness).
TEAE5 treatment-emergent AE.
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DISCUSSION
Human fibrinogen concentrate is now considered the
first-line treatment option for patients with congenital
fibrinogen deficiency. This was a planned interim analysis
of the first, ongoing, prospective, multinational, Phase III
efficacy and safety study of a new double virus-
inactivated/eliminated human fibrinogen concentrate in a
cohort of adult and pediatric patients in the ultrarare set-
ting of congenital afibrinogenemia.
Fibrinogen replacement using this new fibrinogen
concentrate was 100% successful in the treatment of all
acute BEs and for prophylaxis before planned surgery, as
confirmed by an independent adjudication committee.
Significant increases in plasma MCF as a surrogate mea-
sure of hemostatic efficacy were also observed, supporting
the clinical efficacy of this new fibrinogen concentrate in
the control of bleeding. Importantly, no cases required the
use of additional hemostatic interventions such as blood
transfusions or other blood products and treatment with
fibrinogen concentrate showed a good safety profile.
The hemostatic efficacy we observed, for both on-
demand and surgical prophylaxis, mirrors efficacy data
from a previous study investigating treatment with a com-
mercially available fibrinogen concentrate in congenital
fibrinogen deficiency. In a retrospective study, Kreuz and
coworkers18 examined 12 patients with afibrinogenemia,
hypofibrinogenemia, and/or dysfibrinogenemia and,
using a three-point subjective rating scale, reported very
good clinical efficacy for the treatment of on-demand BEs
(n5 26) and most surgical procedures (n5 11). Assess-
ment of comparability with our own data has its chal-
lenges, however, since the criteria used by Kreuz and
coworkers18 to assess efficacy to treat a BE or surgery were
not reported. The peak postinfusion fibrinogen levels
reported in that study (median [range], 145 [48-215] mg/
dL) were slightly higher than we observed; however, this
may be related to the higher doses used in their study.18
Thus, the interim data presented herein are consistent
with previous data and support use of the new fibrinogen
concentrate for on-demand treatment and as prophylaxis
before surgery.
In this first Phase III study performed in afibrinoge-
nemia patients to date, and as described for this interim
analysis, we assessed clinical efficacy of fibrinogen con-
centrate for on-demand treatment and surgical prophy-
laxis using objective four-point criteria, the first time such
criteria have been used in the congenital fibrinogen defi-
ciency setting. Subjective efficacy criteria have been
widely used to assess clinical efficacy in fibrinogen defi-
ciency and other inherited coagulopathies,18,23-25 but eval-
uation of such data is complicated by the use of
subjective, nonstandardized definitions of treatment out-
come.21 Moreover, differences between subjective and
more robust objective efficacy criteria for evaluating
clinical efficacy have been reported.21,26 Supported by the
successful use of objective criteria in the clinical investiga-
tion of other congenital bleeding disorders,21,22 we there-
fore developed objective four-point criteria sets as a more
robust method to determine the hemostatic efficacy of
this new fibrinogen concentrate. Furthermore, all clinical
efficacy assessments were adjudicated by an independent
committee—it is noteworthy that treatment success was
100% for all cases by this adjudication process.
We also assessed hemostatic efficacy using plasma
MCF as a surrogate. In on-demand treatment for acute
BEs, and with a starting plasma MCF of 0.0 mm, we
observed a significant increase in plasma MCF (6.5 mm).
This corroborates the robust clinical outcome data
obtained using the objective clinical assessment criteria.
Therefore, in conjunction with determination of plasma
MCF as a surrogate measure of efficacy with fibrinogen
supplementation,27 the hemostatic efficacy reported here
appears to reflect clinical experience.
The new fibrinogen concentrate demonstrated a
good safety and tolerability profile, consistent with data
reported for other fibrinogen concentrates used for on-
demand and prophylaxis treatment.18,19,28 There were no
deaths, thrombotic events, or seroconversions. AEs
occurred in seven patients and were mostly mild. A single
case of mild skin reaction was deemed possibly related to
fibrinogen concentrate, but resolved with treatment.
Safety data from this interim analysis, which are in line
with those of the Phase II study,20 indicate that the new
fibrinogen concentrate is well tolerated after infusions in
both adult and pediatric patients.
The small number of patients included in this interim
analysis is a limitation. This reflects the difficulty of
recruiting large numbers of patients in a very rare disease
setting. All 13 patients assessed had afibrinogenemia, the
rarest form of deficiency, affecting approximately one in 1
million people.4 With a target enrollment of 24 patients
when completed, this ongoing Phase III efficacy study will
be the largest prospective study of its kind in congenital
fibrinogen deficiency.
In conclusion, interim data from the first Phase III
study indicate that the new fibrinogen concentrate was
successful in the treatment of acute BEs and for surgical
prophylaxis in patients aged at least 12 years with congen-
ital fibrinogen deficiency, with 100% efficacy as assessed
by IDMEAC. Additional hemostatic interventions were not
required for any patient. Fibrinogen concentrate was also
shown to increase clot firmness, consistent with hemo-
static efficacy. Moreover, fibrinogen concentrate achieved
bleeding control with only a single infusion in more
than 90% of patients, showed 100% intraoperative and
postoperative treatment success as rated by investigators
and IDMEAC and was well tolerated. These encouraging
clinical efficacy data confirm and extend our previous
data describing the favorable pharmacokinetic profile of
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this fibrinogen concentrate. Complete data for this first
Phase III study are awaited and will support the further
clinical investigation of this new human fibrinogen
concentrate in patients with congenital fibrinogen
deficiency.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Table S1. Objective four-point criteria sets used for the
clinical assessment of hemostatic efficacy for on-
demand treatment of bleeding episodes and surgical
prophylaxis (intra-operative efficacy and post-operative
efficacy).
LISSITCHKOV ET AL.
422 TRANSFUSION Volume 58, February 2018
